Akeso's (HKG:9926) ivonescimab drug showed strong positive results in a phase 3 trial in China for advanced squamous non-small cell lung cancer, according to a Wednesday filing with the Hong Kong bourse.
The drug also met the primary endpoint of progression-free survival and a favorable safety profile in a trial with 532 enrollees, the filing said.
The trial assessed the capabilities of ivonescimab plus chemotherapy against tislelizumab plus chemotherapy for the treatment of locally advanced or metastatic squamous non-small cell lung cancer, the filing said.
Shares in the drug company nearly 5% during afternoon trading on Wednesday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。